PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing
PacBio (NASDAQ: PACB) and Intus Bio have launched GutID, the first commercial gut health test powered by HiFi sequencing technology. The at-home test combines Intus Bio's Titan-1 platform and PacBio's sequencing capabilities to provide comprehensive microbiome analysis with strain-level resolution.
GutID allows users to collect samples at home and receive detailed reports showing bacteria abundance, including both commensals and pathogens, along with a proprietary microbiome health score and personalized wellness recommendations. The test is particularly beneficial for individuals with IBS, IBD, and those focused on longevity.
This breakthrough addresses limitations of previous microbiome tests that offered low resolution and variable results. The microbiome has been linked to various health outcomes, including cancer, autoimmune, neurodegenerative, and chronic diseases. GutID is now available for purchase at www.gutid.com.
PacBio (NASDAQ: PACB) e Intus Bio hanno lanciato GutID, il primo test commerciale per la salute intestinale alimentato dalla tecnologia di sequenziamento HiFi. Il test a casa combina la piattaforma Titan-1 di Intus Bio e le capacità di sequenziamento di PacBio per fornire un'analisi completa del microbioma con risoluzione a livello di ceppo.
GutID consente agli utenti di raccogliere campioni a casa e ricevere rapporti dettagliati che mostrano l'abbondanza batterica, inclusi sia i commensali che i patogeni, insieme a un punteggio di salute del microbioma proprietario e raccomandazioni per il benessere personalizzate. Il test è particolarmente utile per le persone con IBS, IBD e per chi si concentra sulla longevità.
Questa innovazione affronta i limiti dei test precedenti sul microbioma che offrivano una bassa risoluzione e risultati variabili. Il microbioma è stato collegato a vari esiti di salute, tra cui cancro, malattie autoimmuni, neurodegenerative e croniche. GutID è ora disponibile per l'acquisto su www.gutid.com.
PacBio (NASDAQ: PACB) e Intus Bio han lanzado GutID, la primera prueba comercial de salud intestinal impulsada por tecnología de secuenciación HiFi. La prueba para realizar en casa combina la plataforma Titan-1 de Intus Bio y las capacidades de secuenciación de PacBio para proporcionar un análisis completo del microbioma con resolución a nivel de cepa.
GutID permite a los usuarios recolectar muestras en casa y recibir informes detallados que muestran la abundancia de bacterias, incluidos tanto los comensales como los patógenos, junto con un puntaje de salud del microbioma propietario y recomendaciones personalizadas de bienestar. La prueba es particularmente beneficiosa para las personas con IBS, IBD y aquellas enfocadas en la longevidad.
Este avance aborda las limitaciones de pruebas anteriores del microbioma que ofrecían baja resolución y resultados variables. Se ha vinculado el microbioma a varios resultados de salud, incluyendo cáncer, enfermedades autoinmunes, neurodegenerativas y crónicas. GutID ya está disponible para su compra en www.gutid.com.
PacBio (NASDAQ: PACB)와 Intus Bio는 HiFi 시퀀싱 기술을 기반으로 한 첫 상업적 장 건강 테스트인 GutID를 출시했습니다. 이 자가 테스트는 Intus Bio의 Titan-1 플랫폼과 PacBio의 시퀀싱 기능을 결합하여 균주 수준의 해상도를 갖춘 포괄적인 마이크로바이옴 분석을 제공합니다.
GutID는 사용자가 집에서 샘플을 수집하고, 공생균과 병원균을 포함한 세균의 풍부함을 보여주는 상세 보고서를 받으며, 독점적인 마이크로바이옴 건강 점수와 개인 맞춤형 웰빙 추천을 제공합니다. 이 테스트는 IBS, IBD가 있는 개인 및 장수에 중점을 둔 사람들에게 특히 유용합니다.
이 혁신은 낮은 해상도와 변동적인 결과를 제공했던 이전 마이크로바이옴 테스트의 한계를 다룹니다. 마이크로바이옴은 암, 자가면역 질환, 신경퇴행성 질환 및 만성 질환 등 다양한 건강 결과와 연관되어 있습니다. GutID는 현재 www.gutid.com에서 구매할 수 있습니다.
PacBio (NASDAQ: PACB) et Intus Bio ont lancé GutID, le premier test commercial de santé intestinale propulsé par la technologie de séquençage HiFi. Ce test à domicile combine la plateforme Titan-1 d'Intus Bio et les capacités de séquençage de PacBio pour fournir une analyse complète du microbiome avec une résolution au niveau des souches.
GutID permet aux utilisateurs de collecter des échantillons chez eux et de recevoir des rapports détaillés montrant l'abondance bactérienne, y compris les commensaux et les pathogènes, ainsi qu'un score de santé du microbiome propriétaire et des recommandations de bien-être personnalisées. Ce test est particulièrement bénéfique pour les personnes atteintes d'IBS, d'IBD et celles qui se concentrent sur la longévité.
Cette avancée répond aux limites des tests de microbiome antérieurs qui offraient une faible résolution et des résultats variables. Le microbiome a été lié à divers résultats de santé, y compris le cancer, les maladies auto-immunes, neurodégénératives et chroniques. GutID est maintenant disponible à l'achat sur www.gutid.com.
PacBio (NASDAQ: PACB) und Intus Bio haben GutID eingeführt, den ersten kommerziellen Test für die Darmentgesundheit, der durch HiFi-Sequenziertechnologie unterstützt wird. Der Test für zu Hause kombiniert die Titan-1-Plattform von Intus Bio mit den Sequenzierungsfähigkeiten von PacBio, um eine umfassende Analyse des Mikrobioms mit einer Auflösung auf Stammebene bereitzustellen.
GutID ermöglicht es Benutzern, Proben zu Hause zu sammeln und detaillierte Berichte zu erhalten, die die Bakterienhäufigkeit zeigen, einschließlich sowohl Kommensalen als auch Pathogenen, zusammen mit einem proprietären Mikrobiom-Gesundheitsscore und personalisierten Wellness-Empfehlungen. Der Test ist besonders vorteilhaft für Personen mit IBS, IBD und für diejenigen, die sich auf Langlebigkeit konzentrieren.
Dieser Durchbruch beseitigt die Einschränkungen früherer Mikrobiomtests, die eine niedrige Auflösung und variable Ergebnisse boten. Das Mikrobiom wurde mit verschiedenen gesundheitlichen Ergebnissen in Verbindung gebracht, darunter Krebs, Autoimmunerkrankungen, neurodegenerative Erkrankungen und chronische Krankheiten. GutID ist jetzt über www.gutid.com erhältlich.
- First commercial application of PacBio's technology in human health sector
- Product addresses limitations of existing microbiome tests
- Targets growing markets (IBS, IBD, longevity)
- Immediate commercial availability
- None.
Insights
The launch of GutID represents a strategic expansion into the rapidly growing consumer healthcare diagnostics market, estimated at
The collaboration with Intus Bio is particularly notable as it marks PacBio's first commercial application in human health, opening doors to the lucrative clinical diagnostics sector. The microbiome testing market has seen a CAGR of
The key differentiator for GutID is its strain-level resolution capability, which addresses a critical gap in current microbiome testing offerings. This technological advantage could command premium pricing and higher margins compared to existing solutions, potentially improving PacBio's financial metrics.
The technical breakthrough here lies in combining PacBio's long-read sequencing with Intus Bio's Titan-1 platform, enabling unprecedented strain-level bacterial identification. This is important because strain-specific variations can significantly impact therapeutic responses and health outcomes.
The platform's ability to differentiate between commensals and pathogens with high accuracy addresses a major limitation of short-read sequencing technologies. This precision could be particularly valuable for clinical applications in personalized medicine, especially for conditions like IBD and IBS where strain-specific interventions are crucial.
Think of it like having a high-resolution camera that can distinguish between identical twins (bacterial strains) versus a low-resolution one that can only tell that they're siblings (species level). This precision is game-changing for therapeutic development and clinical decision-making.
The direct-to-consumer launch strategy taps into the growing trend of personalized health monitoring, with the global microbiome market projected to reach
The endorsement from healthcare professionals and focus on actionable insights addresses key market demands. Particularly noteworthy is the inclusion of a proprietary health score and personalized recommendations, features that typically drive higher customer engagement and retention rates in the diagnostics sector.
For investors, this represents PacBio's strategic pivot from a pure technology provider to a consumer-facing healthcare company, potentially leading to more predictable revenue streams and higher valuation multiples typical of diagnostic companies.
MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform and PacBio’s HiFi sequencing technology. By combining Intus Bio’s patented strain-level resolution assay and AI-powered analysis with PacBio’s renowned sequencing accuracy, GutID sets a new benchmark in gut microbiome testing, and is the only comprehensive and accurate gut microbiome test available today.
Offering the highest resolution analysis possible, GutID is a major breakthrough as it delivers robust and repeatable results, which can be used with confidence to help understand and manage the microbiome, a known critical driver of health outcomes including cancer.
“We are proud to partner with PacBio for their first human health-related commercial application,” said Paul Denslow, CEO of Intus Bio. “High accuracy, long-read sequencing is essential to Intus Bio’s ability to unlock the microbiome, making GutID not just a test, but a transformative tool for understanding and improving human health. It’s already having an incredible impact.”
Recommended by healthcare professionals, GutID provides previously unobtainable gut health information. The test lets the user easily collect and ship a sample from home to a state-of-the-art lab, where PacBio’s long-read sequencing and Intus Bio’s Titan-1 platform combine to power comprehensive, actionable reports.
Each report includes a detailed visualization of bacteria down to the strain level, showing the abundance of both commensals and pathogens. Users also receive a proprietary microbiome health score and personalized recommendations to optimize gut and overall wellness.
GutID is already transforming the lives of individuals with IBS, IBD, and those focused on longevity by offering insights which were previously unavailable.
“We are thrilled to see Intus Bio leveraging PacBio’s advanced sequencing solutions to uncover microbial communities far beyond traditional methods,” said David Miller, Vice President of Marketing at PacBio. GutID showcases the transformative power of our long-read sequencing platforms, opening new frontiers in healthcare by providing deeper insights into the human microbiome and improving human health.”
The microbiome - the vast collection of bacteria in every human - is well established as a critical driver of health outcomes. It has been associated with cancer, autoimmune, neurodegenerative, and other chronic diseases as well as behavioral disorders. A complete, accurate and detailed view of the bacterial microbiome is central to actionability, allowing interventions and lifestyle changes to be made and tracked with confidence.
Despite the microbiome’s well understood potential to impact healthcare, previous generations of microbiome tests have been low resolution, resulting in variable results and limited utility for improving and managing health. By combining Intus Bio’s strain-level microbiome platform and the power of PacBio’s sequencing technology, GutID offers both consumers and clinicians repeatable and robust results for actionable insights.
GutID is now available for purchase at www.gutid.com. For more information about the technology behind GutID and how it can support health and wellness, visit www.intusbio.com and www.pacb.com.
About PacBio:
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About Intus Bio:
Intus Bio is transforming the role of the microbiome in healthcare through the development of cutting-edge technology to allow the complexity of the microbiome to be truly seen and understood for the first time. This approach is supporting next generation tests for patients and clinicians to improve health outcomes, and microbiome discoveries with the promise of a new class of tools for the detection, treatment, and prevention of chronic diseases. Powered by the proprietary Titan-1 platform, Intus Bio is making the microbiome as important to healthcare as it is to health.
Forward Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, coverage, advantages, and benefits or expected benefits of using, PacBio products or technologies, including the use of HiFi sequencing technology in connection with Intus Bio’s GutID; use of GutID to help understand and manage the microbiome and to open new frontiers in healthcare; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in commercializing a new product, the difficulty of generating discoveries in the microbiome; potential performance and quality issues; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
PacBio
For investors: Todd Friedman, IR@pacificbiosciences.com
For media: PR@pacificbiosciences.com
Intus Bio
For investors: paul.denslow@intusbio.com
For media: soo.kang@intusbio.com
FAQ
What is GutID and how does it use PACB's technology?
How does the GutID test process work for customers?
What medical conditions can benefit from PACB's GutID test?
How does PACB's GutID differ from existing microbiome tests?
What health conditions can be analyzed using PACB's GutID test?
